CDK
Los inhibidores de las quinasas dependientes de ciclina (CDK) son compuestos que bloquean la actividad de las CDK, un grupo de quinasas de proteínas que regulan el ciclo celular, la transcripción y otros procesos celulares. Las CDK se activan al unirse a las ciclinas, y su actividad es crucial para la progresión de las células a través de las diferentes fases del ciclo celular. Inhibir las CDK puede detener la división celular, provocando la detención del ciclo celular y la apoptosis, especialmente en células cancerosas donde las CDK a menudo están desreguladas. Los inhibidores de CDK se utilizan ampliamente en la investigación del cáncer y tienen un potencial terapéutico en el tratamiento de varios tipos de cáncer. En CymitQuimica, ofrecemos una selección completa de inhibidores de CDK de alta calidad para apoyar su investigación en el control del ciclo celular, el cáncer y el desarrollo terapéutico.
Se han encontrado 500 productos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Cdc7-IN-1
CAS:<p>Cdc7-IN-1: selective ATP-competitive Cdc7 kinase inhibitor; IC50 0.6 nM at 1mM ATP; induces cancer cell death.</p>Fórmula:C21H16ClN3O4Forma y color:SolidPeso molecular:409.82CDK9-IN-14
CAS:<p>CDK9-IN-14: Potent CDK9 inhibitor, IC50=6.92 nM, effective on MV-4-11 cells and in vivo tumors, low toxicity, minimal side effects.</p>Fórmula:C21H23F2N3O4Forma y color:SolidPeso molecular:419.42CLK1/2-IN-3
CAS:<p>CLK1/2-IN-3 (Cpd-3) is a CLK1 and CLK2 inhibitor with antiproliferative activity that inhibits the activity of CLK and SRPK.</p>Fórmula:C21H21N5O2Pureza:99.04%Forma y color:SolidPeso molecular:375.42THZ1-R
CAS:<p>THZ1-R is a non-covalent active analogue of THZ1, with the acrylamide group removed from THZ1, not covalently bind to the C312 cysteine residue of CDK7.</p>Fórmula:C31H30ClN7O2Pureza:98%Forma y color:SolidPeso molecular:568.07CLK1-IN-1
CAS:<p>CLK1-IN-1 is a potent and selective inhibitor of the Cdc2-like kinase 1 (CLK1; IC50: 2 nM).</p>Fórmula:C24H16FN5OForma y color:SolidPeso molecular:409.42CDK12-IN-E9
CAS:<p>CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and non-covalent CDK9 inhibitor while avoiding ABC transporter-mediated efflux.</p>Fórmula:C24H30N6O2Forma y color:SolidPeso molecular:434.53Cdc7-IN-17
CAS:<p>Cdc7-IN-17 is a potent inhibitor of CDC7 with an IC 50 of <10 μM that can be used in cancer research [1].</p>Fórmula:C13H15N5OSForma y color:SolidPeso molecular:289.36AS2863619 free base
CAS:<p>AS2863619 free base enables the conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells.</p>Fórmula:C16H12N8OForma y color:SolidPeso molecular:332.32Cdc7-IN-4
CAS:<p>Cdc7-IN-4 is a potent inhibitor of Cdc7 kinase.</p>Fórmula:C22H24F3N5O4Pureza:98%Forma y color:SolidPeso molecular:479.45K 00546
CAS:<p>K00546 inhibits CDK1/cyclin B (IC50: 0.6 nM), CDK2/cyclin A (IC50: 0.5 nM), CLK1 (IC50: 8.9 nM), and CLK3 (IC50: 29.2 nM).</p>Fórmula:C15H13F2N7O2S2Pureza:99.12%Forma y color:SolidPeso molecular:425.44CDK8-IN-7
CAS:<p>CDK8-IN-7 is a potent CDK8 inhibitor with a Kd of 3.5 nM, showing promise for AML research.</p>Fórmula:C30H40N2Forma y color:SolidPeso molecular:428.65Cdc7-IN-15
CAS:<p>Cdc7-IN-15 (Example 108) is an inhibitor of cdc7 kinase that has potential to be used for cancer research [1].</p>Fórmula:C12H14N4OSForma y color:SolidPeso molecular:262.33CP681301
CAS:<p>CP681301 is a potent CDK5 inhibitor with anti-tumor effects in Drosophila and reduces Glioma stem cells' growth and renewal.</p>Fórmula:C17H22N4OForma y color:SolidPeso molecular:298.38MDK6204
CAS:<p>MDK6204 is a selective inhibitor of CLK1 and CLK2.</p>Fórmula:C20H20N6OPureza:98%Forma y color:SolidPeso molecular:360.41BSJ-01-175
CAS:<p>BSJ-01-175: Selective, potent covalent inhibitor of CDK12/13, targets cancer cells, inhibits phosphorylated RNA polymerase II, downregulates CDK12 genes.</p>Fórmula:C30H33ClN6O2Forma y color:SolidPeso molecular:545.08Indirubin-3'-monoxime-5-sulphonic acid
CAS:<p>Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of GSK-3β, CDK5, and CDK1 with IC50s of 80nM,5 nM, and 7 nM, respectively.</p>Fórmula:C16H11N3O5SPureza:98%Forma y color:SolidPeso molecular:357.34CDK7-IN-13
CAS:<p>CDK7-IN-13: A potent pyrimidine-based CDK7 inhibitor, potential for various cancers. See CN114249712A.</p>Fórmula:C20H23F3N6OSPureza:99.22%Forma y color:SolidPeso molecular:452.5P18IN003
CAS:<p>P18IN003 is a selective and effective p18(INK4C) inhibitor that inhibits the activity of p18 protein and can be used to study in vitro expansion of</p>Fórmula:C17H16N2O3Pureza:98.77%Forma y color:SolidPeso molecular:296.32CDK7-IN-20
<p>CDK7-IN-20: potent, irreversible CDK7 inhibitor, IC50 of 4nM, 206x selectivity vs. other CDKs, potential for ADPKD study.</p>Fórmula:C30H26N6O3Forma y color:SolidPeso molecular:518.57FLT3/CDK4-IN-1
CAS:<p>FLT3/CDK4-IN-1: Oral FLT3 (7 nM IC50) & CDK4 (11 nM IC50) inhibitor with strong in vivo anti-cancer properties.</p>Fórmula:C25H28F2N8Forma y color:SolidPeso molecular:478.54BS-181
CAS:<p>BS-181 is a highly selective CDK7 inhibitor (IC50: 21 nM); >40-fold selective for CDK7 than CDK1/2/4/5/6/9.</p>Fórmula:C22H32N6Pureza:98%Forma y color:SolidPeso molecular:380.53CDK4/6-IN-12
CAS:<p>CDK4/6-IN-12 inhibits CDK4/6 with IC50s of 592.3 nM & 3090 nM, useful in cancer research.</p>Fórmula:C12H10N6Forma y color:SolidPeso molecular:238.25CGP60474
CAS:<p>CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC.</p>Fórmula:C18H18ClN5OPureza:98.81%Forma y color:SolidPeso molecular:355.82CCT068127
CAS:<p>CCT068127 is a potent CDK2 and CDK9 inhibitor.</p>Fórmula:C19H27N7OForma y color:SolidPeso molecular:369.46(S)-CR8
CAS:<p>(S)-CR8 is an effective second-generation cyclin-dependent kinase inhibitor.</p>Fórmula:C24H29N7OForma y color:SolidPeso molecular:431.53CDK7-IN-8
CAS:<p>CDK7-IN-8 is a potent inhibitor of CDK7 (IC50: 54.29 nM) and exhibits inhibitory activity against several cancer cells and in vivo tumor models.</p>Fórmula:C25H38N8O3Forma y color:SolidPeso molecular:498.62EGFR/HER2/CDK9-IN-3
CAS:<p>EGFR/HER2/CDK9-IN-3 inhibits EGFR (191.08 nM IC50), HER2 (132.65 nM), CDK9 (113.98 nM); shows anti-tumor effects.</p>Fórmula:C24H21N3O4S2Forma y color:SolidPeso molecular:479.57Aloisine A
CAS:<p>Aloisine A, a CDK/GSK-3 inhibitor with IC50: Cdk1/B-150nM, Cdk2/A-120nM, Cdk2/E-400nM, Cdk5/25-200nM, Cdk5/35-160nM, GSK-3α-500nM, GSK-3β-650nM, JNK-3-10μM.</p>Fórmula:C16H17N3OPureza:98%Forma y color:SolidPeso molecular:267.33TP1287
CAS:<p>TP-1287 is an oral phosphate prodrug of the CDK9 inhibitor, alvocidib.</p>Fórmula:C21H21ClNO8PForma y color:SolidPeso molecular:481.82Indirubin-5-sulfonate
CAS:<p>Indirubin-5-sulfonate inhibits GSK-3β & CDKs with IC50: 55/35/150/300/65 nM for CDK1/B, 2/A&E, 4/D1, 5/p35.</p>Fórmula:C16H10N2O5SPureza:98%Forma y color:SolidPeso molecular:342.33Crozbaciclib fumarate
CAS:<p>Crozbaciclib fumarate is a CDK4/6 inhibitor with IC 50 s of 3 and 1 nM, respectively.</p>Fórmula:C32H34F2N6O4Forma y color:SolidPeso molecular:604.65CDK7-IN-12
CAS:<p>CDK7-IN-12 inhibits CDK7 to control transcription and cell cycle, halting tumor growth in vitro/vivo with cancer research potential.</p>Fórmula:C20H19F3N6Forma y color:SolidPeso molecular:400.4CDK1-IN-1
CAS:<p>CDK1-IN-7 inhibits CDK1 at 161.2 nM, triggers p53-dependent apoptosis, and selectively targets tumor growth.</p>Fórmula:C27H23N5O3Forma y color:SolidPeso molecular:465.5CDK4/6-IN-9
CAS:<p>CDK4/6-IN-9 selectively inhibits CDK4/6 (IC50: 905 nM); potential for MM research.</p>Fórmula:C22H23FN8Forma y color:SolidPeso molecular:418.47Cdc7-IN-13
CAS:<p>Cdc7-IN-13 (compound 84) is a highly potent CDC7 inhibitor, exhibiting an IC50 value of <1 nM. This compound holds promise for cancer research [1].</p>Fórmula:C18H20N4O2SForma y color:SolidPeso molecular:356.44Ulecaciclib
CAS:<p>Ulecaciclib: oral, BBB-permeable CDK inhibitor; favorable pharmacokinetics; ki: 0.62 μM (CDK2/A), 3 nM (CDK6/D3), 0.2 nM (CDK4/D1), 0.63 μM (CDK7/H).</p>Fórmula:C25H33FN8SForma y color:SolidPeso molecular:496.65FN-1501
CAS:<p>FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively).</p>Fórmula:C22H25N9OPureza:97.4%Forma y color:SolidPeso molecular:431.49JTK-101
CAS:<p>JTK-101 is a potent and selective Tat-dependent HIV-1 replication inhibitor.</p>Fórmula:C25H23N3O3Forma y color:SolidPeso molecular:413.47(E/Z)-BIO-acetoxime
CAS:<p>(E/Z)-BIO-acetoxime: potent GSK-3 α/β inhibitor; IC50: GSK-3α/β 10nM, CDK5/p25 2.4μM, CDK2/A 4.3μM, CDK1/B 63μM.</p>Fórmula:C18H12BrN3O3Forma y color:SolidPeso molecular:398.21(S)-LY3177833 hydrate
CAS:<p>(S)-LY3177833 ((S)-Example 2) hydrate, an orally active CDC7 kinase inhibitor, exhibits extensive in vitro anticancer efficacy.</p>Fórmula:C16H14FN5O2Forma y color:SolidPeso molecular:327.31RP-106
CAS:<p>RP-106 is an ATP-competitive inhibitor of CDK5/p25, CDK1/cyclin B, and GSK-3.</p>Fórmula:C17H19N3OPureza:98%Forma y color:SolidPeso molecular:281.35PKC-9
CAS:<p>PKC-9 is a PKC-zeta inhibitor 9.</p>Fórmula:C25H25N7Forma y color:SolidPeso molecular:423.51CDK4/6-IN-7
CAS:<p>CDK4/6-IN-7 is an oral, potent CDK4/6 inhibitor with IC50s of 1.58/4.09 nM, crucial for breast cancer studies.</p>Fórmula:C18H18ClN5O3Forma y color:SolidPeso molecular:387.82Cdc7-IN-3
CAS:<p>Cdc7-IN-3 is a potent inhibitor of Cdc7 kinase.</p>Fórmula:C20H22N4O5Pureza:98%Forma y color:SolidPeso molecular:398.41CDK7-IN-2
CAS:<p>CDK7-IN-2 inhibits CDK7, essential for RNA polymerase II activation and cell cycle control, with cancer research potential.</p>Fórmula:C26H39N7O3Forma y color:SolidPeso molecular:497.63EGFR/HER2/CDK9-IN-1
CAS:<p>EGFR/HER2/CDK9-IN-1 is a potent inhibitor (IC50: EGFR 90.17 nM, HER2 131.39 nM, CDK9 67.04 nM) with notable anti-tumor activity.</p>Fórmula:C23H21N3O3S2Forma y color:SolidPeso molecular:451.56CDK5 inhibitor 20-223
CAS:<p>CDK5 inhibitor 20-223 is a potent CDK2/CDK5 inhibitor,anti-Colorectal Cancer (CRC), inhibiting cell migration and inducing cell cycle arrest.</p>Fórmula:C19H19N3OForma y color:SolidPeso molecular:305.37FN-1501-propionic acid
CAS:<p>FN-1501-propionic acid, a CDK2/9 ligand, in conjunction with a CRBN ligand, has been utilized in the design of a PROTAC CDK2/9 degrader.</p>Fórmula:C25H27N9O4Pureza:98%Forma y color:SolidPeso molecular:517.54EGFR/HER2/CDK9-IN-2
CAS:<p>EGFR/HER2/CDK9-IN-2 inhibits EGFR, HER2, CDK9 with IC50s: 145.35, 129.07, 117.13 nM; strong antitumor effects.</p>Fórmula:C23H20N4O5S2Forma y color:SolidPeso molecular:496.56CDK8-IN-10
CAS:<p>CDK8-IN-10 is a selective and potent inhibitor of cell cycle protein-dependent kinase (CDK8) (IC50: 8.25 nM) that can be used to study cancer.</p>Fórmula:C25H15ClF3N5O3Forma y color:SolidPeso molecular:525.87CDK4/6-IN-8
CAS:<p>CDK4/6-IN-8 (Compound 7p) is a selective inhibitor of CDK4 (IC50=5.01 nM) and CDK6 (IC50=3.97 nM).</p>Fórmula:C18H18N6O5Forma y color:SolidPeso molecular:398.37AS-0141
CAS:<p>AS-0141 (Cdc7-IN-6) 是一种有效的 Cdc7 激酶抑制剂 (IC50=4 nM)，具有抗肿瘤活性。Cdc7 是一种丝氨酸苏氨酸蛋白激酶酶，在细胞周期中对 DNA 复制的启动至关重要。</p>Fórmula:C21H22F3N5O4Pureza:99.97%Forma y color:SolidPeso molecular:465.43Ryuvidine
CAS:<p>Ryuvidine is a dual inhibitor of KDM5A and SETD8, an inducer of the DNA damage response, and can be used to study breast cancer and erythroderma.</p>Fórmula:C15H12N2O2SPureza:98.6%Forma y color:SolidPeso molecular:284.33(S)-Enitociclib
CAS:<p>(S)-Enitociclib (VIP152) is a selective CDK9 inhibitor that inhibits the transcription of anti-apoptotic and pro-survival proteins.</p>Fórmula:C19H18F2N4O2SPureza:98.98%Forma y color:SolidPeso molecular:404.43CLK-IN-T3
CAS:<p>CLK-IN-T3 is an inhibitor of CLK1, CLK2, and CLK3 with IC50s of 0.67, 15, and 110 nM. CLK-IN-T3 exhibits anti-cancer activity.</p>Fórmula:C28H30N6O2Pureza:99.61%Forma y color:SolidPeso molecular:482.58(S)-PF-06873600
CAS:<p>(S)-PF-06873600 is the S enantiomer of PF-06873600 which is an inhibitor of CDK.</p>Fórmula:C20H27F2N5O4SPureza:98.59%Forma y color:SolidPeso molecular:471.52CDK9-IN-10
CAS:<p>CDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2.</p>Fórmula:C22H16O5Pureza:99.8%Forma y color:SolidPeso molecular:360.36PS423
CAS:<p>PS423 is a substrate-selective protein kinase PDK1 inhibitor that acts by binding to the PIF-pocket allosteric docking site.</p>Fórmula:C25H23F3O9Pureza:98.81% - 99.26%Forma y color:SolidPeso molecular:524.44HTH-01-091
CAS:<p>HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor (IC50: 10.5 nM).HTH-01-091 inhibits PIM1/2/3, RIPK2, DYRK3,</p>Fórmula:C26H28Cl2N4O2Pureza:98.4%Forma y color:SolidPeso molecular:499.43hSMG-1 inhibitor 11e
CAS:<p>hSMG-1 inhibitor 11e is an effective and selective inhibitor of hSMG-1 (IC50 <0.05 nM) and can be used in studies about cancer treatment.</p>Fórmula:C26H27N7O3SPureza:99.89%Forma y color:SolidPeso molecular:517.6CDK-IN-2
CAS:<p>CDK-IN-2 (CDK inhibitor II) is a potent and specific CDK9 inhibitor (IC50: <8 nM).</p>Fórmula:C18H19ClFN3O2Pureza:99.67%Forma y color:SolidPeso molecular:363.819-Isopropylolomoucine
CAS:<p>9-Isopropylolomoucine (N9-Isopropylolomoucine), a cell cycle protein-dependent kinase inhibitor, is a thiopurine.</p>Fórmula:C17H22N6OPureza:99.82%Forma y color:SolidPeso molecular:326.4CDK8-IN-1
CAS:<p>CDK8-IN-1 is a selective CDK8 inhibitor (IC50: 3 nM).</p>Fórmula:C11H8F3N3OPureza:98.48%Forma y color:SolidPeso molecular:255.2Cdc7-IN-7c
CAS:<p>Cdc7-IN-7c (Cdc7 inhibitor-7c) has antitumor activity and has inhibitory effect on liver cancer, lung cancer, kidney cancer, brain cancer and cervical cancer.</p>Fórmula:C15H17N5OSPureza:98.19% - 99.22%Forma y color:SolidPeso molecular:315.39SEL120-34A
CAS:<p>SEL120-34A inhibits CDK8 (IC50: 4.4 nM) & CDK19 (10.4 nM), less on CDK9 (1070 nM), has antitumor properties.</p>Fórmula:C15H18Br2N4Pureza:99.764% - 99.84%Forma y color:SolidPeso molecular:414.14CDK4/6/1 Inhibitor
CAS:<p>CDK4/6/1 Inhibitor (Crozbaciclib) is a type of CDK4/6 inhibitor (IC50s: 3 and 1 nM).</p>Fórmula:C28H30F2N6Pureza:99.26% - 99.72%Forma y color:SolidPeso molecular:488.57BML-259
CAS:<p>BML-259 inhibits CDK5/CDK2 (IC50: 64/98 nM) for cancer and neurodegeneration research.</p>Fórmula:C14H16N2OSPureza:99.84%Forma y color:SolidPeso molecular:260.35dCeMM2
CAS:<p>dCeMM2 degrades glue by promoting CDK12-cyclin K ubiquitination and degradation via CRL4B ligase interaction.</p>Fórmula:C16H11ClN6OSPureza:99.68%Forma y color:SolidPeso molecular:370.82Cdk2 Inhibitor II
CAS:<p>Cdk2 Inhibitor II is a selective and potent CDK2 inhibitor50 at 60 nM.</p>Fórmula:C14H11BrN4O3SPureza:97.07%Forma y color:SolidPeso molecular:395.23Abemaciclib metabolite M20
CAS:<p>Abemaciclib metabolite M20 (CDK4/6-IN-4) 是 Abemaciclib 的活性代谢物。 Abemaciclib metabolite M20 是一种特异性 CDK4/6 抑制剂，可用于癌症治疗的相关研究。</p>Fórmula:C27H32F2N8OPureza:98.1% - 99.08%Forma y color:SolidPeso molecular:522.59SHP2/CDK4-IN-1
CAS:<p>SHP2/CDK4-IN-1: dual inhibitor, oral, potent (IC50: SHP2 4.3 nM, CDK4 18.2 nM), hinders TNBC growth, strong antitumor effects in mice.</p>Fórmula:C33H35ClF2N10OSForma y color:SolidPeso molecular:693.21CDK-IN-11
CAS:<p>CDK-IN-11, a heterocyclic compound, promotes cardiomyocyte maturation [1].</p>Fórmula:C25H21BrN4O2Forma y color:SolidPeso molecular:489.36CDK/HDAC-IN-3
CAS:<p>CDK/HDAC-IN-3 is an orally active dual inhibitor of HDACs and CDKs, offering potent and selective inhibition of CDK9, CDK12, CDK13, HDAC1, HDAC2, and HDAC3,</p>Fórmula:C24H18Cl2N6O3Pureza:98%Forma y color:SolidPeso molecular:509.34Cdk4 Inhibitor
CAS:<p>PD 0332991, an unsymmetrical indolocarbazole compound, is cell-permeable and exhibits antiproliferative effects by functioning as a potent, selective, reversible, and ATP-competitive inhibitor of Cdk4/D1 (IC 50 = 76 nM). Although it can inhibit other Cdks, such as Cdk2/E and Cdk1/B, effectiveness requires higher concentrations (IC 50 = 520 nM and 2.1 µM, respectively) and demonstrates minimal activity against CaMKII, PKA, or GSK-3β (IC 50 ≥ 12.4 µM). PD 0332991 efficiently inhibits tumor cell growth in HCT-116 and NCI-H460 cell lines with an IC 50 < 3.0 µM, primarily through blocking Rb phosphorylation and inducing G1 cell cycle arrest.</p>Fórmula:C20H10BrN3O2Forma y color:SolidPeso molecular:404.2EHT 5372
CAS:<p>EHT 5372 inhibits DYRK kinases; IC50: 0.22-221 nM for DYRK1A/B, DYRK2/3, CLK1/2/4, GSK-3α/β.</p>Fórmula:C17H11Cl2N5OSForma y color:SolidPeso molecular:404.27Nε-(1-Carboxyethyl)-L-lysine
CAS:<p>Nε-(1-Carboxyethyl)-L-lysine (CEL) is an advanced glycation end-product (AGE). Exposure to CEL reduces glutamate uptake and S100B secretion in the hippocampus.</p>Fórmula:C9H18N2O4Forma y color:SolidPeso molecular:218.25Lerociclib
CAS:<p>Lerociclib (G1T38) is a CDK4/6 inhibitor with anticancer and antitumor activities, inhibiting CDK4/CyclinD1 and CDK6/CyclinD3.</p>Fórmula:C26H34N8OPureza:99%Forma y color:SolidPeso molecular:474.6CDK8-IN-3
CAS:<p>CDK8-IN-3 is an inhibitor of CDK8.</p>Fórmula:C22H23N5O2Pureza:98%Forma y color:SolidPeso molecular:389.45CDK9-IN-29
CAS:<p>CDK9-IN-29 (compound Z11) is a potent inhibitor of CDK9, exhibiting high kinase selectivity and an IC50 value of 3.20 nM.</p>Fórmula:C29H33F2N5O4Pureza:98%Forma y color:SolidPeso molecular:553.6IIIM-290
CAS:<p>IIIM-290 is an oral CDK inhibitor (IC50s: 90 and 94 nM for CDK2/A and CDK9/T1).</p>Fórmula:C23H21Cl2NO5Pureza:98%Forma y color:SolidPeso molecular:462.32CCT-251921
CAS:<p>CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor (IC50: 2.3 nM).</p>Fórmula:C21H23ClN6OPureza:99.07%Forma y color:SolidPeso molecular:410.9CDK9-IN-8
CAS:<p>CDK9-IN-8 is a highly potent and selective CDK9 inhibitor (IC50: 12 nM).</p>Fórmula:C31H32FN7O3Pureza:99.54%Forma y color:SolidPeso molecular:569.63QR-6401
CAS:<p>QR-6401, a selective macrocyclic CDK2 inhibitor, is orally active with IC50 values of 0.37 nM for CDK2/E1, 10 nM for CDK9/T1, 22 nM for CDK1/A2, 34 nM for CDK6/</p>Fórmula:C19H23N5O3Pureza:98%Forma y color:SolidPeso molecular:369.42Tacaciclib
CAS:<p>Tacaciclib is a cyclin-dependent kinase (CDK) inhibitor with observed antineoplastic activity [1].</p>Fórmula:C30H36N6O3Pureza:98%Forma y color:SolidPeso molecular:528.65Mevociclib
CAS:<p>Mevociclib (SY-1365) is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors.</p>Fórmula:C31H35ClN8O2Pureza:98.02% - 98.02%Forma y color:SolidPeso molecular:587.11Palbociclib orotate
CAS:<p>Palbociclib (PD 0332991) orotate, an orally active selective inhibitor of CDK4 and CDK6, exhibits IC50 values of 11 and 16 nM, respectively.</p>Fórmula:C29H33N9O6Pureza:98%Forma y color:SolidPeso molecular:603.63KM05382
CAS:<p>KM05382 inhibits CDK9 and the transcription of GAPDH.</p>Fórmula:C20H19ClN2O3S2Forma y color:SolidPeso molecular:434.96CDK4-IN-2
CAS:<p>CDK4-IN-2 (A17) is a potent inhibitor of CDK4, exhibiting K i and IC 50 values of less than 10 nM and is utilized in cancer research [1].</p>Fórmula:C22H26F2N6O4SPureza:98%Forma y color:SolidPeso molecular:508.54DCB-3503
CAS:<p>DCB-3503, a tylophorine analog, may fight cancer and aid immunosuppression by hindering protein synthesis and modulating HSC70 ATPase function.</p>Fórmula:C24H27NO5Forma y color:SolidPeso molecular:409.47LDC3140
CAS:<p>LDC3140 is a potent inhibitor of Cyclin-dependent kinase 7 (CDK7).</p>Fórmula:C23H33N7OPureza:98%Forma y color:SolidPeso molecular:423.55Leucettinib-92
CAS:<p>Leucettinib-92 (compound 92) is a kinase inhibitor selective for DYRK/CLK families, displaying IC50 values of 147 nM (CLK1), 39 nM (CLK2), 5.2 nM (CLK4), 0.8 μM</p>Fórmula:C21H22N4OSPureza:98%Forma y color:SolidPeso molecular:378.49CDK9-IN-9
CAS:<p>CDK9-IN-9 is a potent and selective CDK9 inhibitor (IC50: 1.8 nM) with anti-cancer activity. It inhibits CDK2 (IC50: 155 nM).</p>Fórmula:C22H23F2N5O2SPureza:98%Forma y color:SolidPeso molecular:459.51(2S,3R)-Voruciclib
CAS:<p>(2S,3R)-Voruciclib is the (2S,3R)-enantiomer of Voruciclib. It is an orally active CDK inhibitor.</p>Fórmula:C22H19ClF3NO5Pureza:98%Forma y color:SolidPeso molecular:469.84CDK9-IN-2
CAS:<p>CDK9-IN-2, a CDK9 inhibitor from patent WO/2012131594A1, IC50: 5 nM in A2058, 7 nM in H929 at 72hr.</p>Fórmula:C23H25ClFN5Pureza:99%Forma y color:SolidPeso molecular:425.93CDK7-IN-14
CAS:<p>CDK7-IN-14, a potent CDK7 inhibitor from pyrimidines, may treat transcriptionally dysregulated cancers (CN114249712A).</p>Fórmula:C22H24F3N6OPForma y color:SolidPeso molecular:476.435-Iodo-indirubin-3'-monoxime
CAS:<p>5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase (IC50s</p>Fórmula:C16H10IN3O2Forma y color:SolidPeso molecular:403.17NU6300
CAS:<p>NU6300 is a covalent CDK2 inhibitor exhibiting irreversible and ATP-competitive properties and also functions as a GSDMD (Gasdermin D) inhibitor.</p>Fórmula:C20H23N5O3SPureza:96.08%Forma y color:SolidPeso molecular:413.49Voruciclib hydrochloride
CAS:<p>Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM).</p>Fórmula:C22H20Cl2F3NO5Pureza:98%Forma y color:SolidPeso molecular:506.3PF-6808472
CAS:<p>PF-6808472 is a cell-permeable covalent kinase probe, reacts with conserved lysine residues within the ATP-binding site of kinases.</p>Fórmula:C25H27FN8O3SPureza:99.02%Forma y color:SolidPeso molecular:538.6CDK7-IN-22
CAS:<p>CDK7-IN-22 (compound 101) is a selective CDK7 inhibitor that exhibits antitumor activity, demonstrating specificity for CDK7 [1].</p>Fórmula:C22H25F3N6Pureza:98%Forma y color:SolidPeso molecular:430.47
